SM
VTGN icon

Sabby Management’s VistaGen Therapeutics VTGN Stock Holding History

Sabby Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-115
Closed -$1.14M – 138
2022
Q2 		$1.14M Buy
115
+10
+10% +$353 0.77% 26
2022
Q1 		$389K Sell
105
-6
-5% -$262 0.06% 71
2021
Q4 		$651K Buy
111
+103
+1,288% +$6.7K 0.09% 96
2021
Q3 		$67K Buy
+8
New +$695 0.01% 167

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sabby Management's VTGN Position: Q2 2018 in Review

Sabby Management sold out of VistaGen Therapeutics (VTGN) in Q2 2018, closing a stake of 4,783 shares — an estimated $133K sold.

Sabby Management first reported a position in VTGN in Q2 2016 and held it in 7 quarters. The position peaked at $2.43M in Q2 2016. 22 funds tracked by Wall St. Rank hold VTGN as of Q2 2018.

  • Sabby Management reported no remaining VistaGen Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Sabby Management sold 4,783 VistaGen Therapeutics shares in Q2 2018, an estimated $133K.
  • Sabby Management first reported a position in VistaGen Therapeutics in Q2 2016 and held it in 7 quarters.
  • Sabby Management's VistaGen Therapeutics position peaked at $2.43M in Q2 2016.
  • 22 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.